## => d ibib abs 19 1-5

L9 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2003:409169 HCAPLUS

DOCUMENT NUMBER:

138:380506

TITLE:

Genes that are differentially expressed during

erythropoiesis and their diagnostic and therapeutic

uses

INVENTOR (S):

Brissette, William H.; Neote, Kuldeep S.; Zagouras,

Panayiotis; Zenke, Martin; Lemke, Britt; Hacker,

Christine

PATENT ASSIGNEE(S):

Pfizer Products Inc., USA; Max-Delbrueck-Centrum Fuer

Molekulare Medizin

SOURCE:

PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

	PATENT NO.				KIND DATE			APPLICATION NO.				DATE						
	WO	2003	0381	30		A2	_	2003	0508		WO 2	002-	XA34	888		2	0021	031
		W:	AE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KZ,	·LC,	LK,	LR,
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
			PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,
			UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	AZ,	BY,	KG,	KZ,	MD,	RU,
			TJ,	TM														
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,
			CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		,	PT,	SE,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,
			NE,	SN,	TD,	TG												
	WO	2003	0381	30		A2		2003	0508		WO 2	002-1	US34	888		2	0021	031
	WO	2003	0381	30		<b>A3</b>		2004	0212									
	WO	2003	0381	30		C1		2004	0422									
		W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
			PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
			UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW							
		RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
			KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
			FI,	FR,	GΒ,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	ВJ,	CF,
			CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
PRIO	RITY	APP	LN.	INFO	. :						US 2	001-	3350	48P	]	P 20	0011	031
										1	US 2	001-3	3351	33P	]	P 20	0011	102
										1	WO 2	002-1	JS34	888	1	A 20	0021	031
AB	The	nre	sent	inve	entid	on n	rovi	des	nol	tar	nets	that	t red	nılat		rvth	ropo:	iesis

AB The present invention provides mol. targets that regulate erythropoiesis.

Groups of genes or their encoded gene products comprise panels of the invention and may be used in therapeutic intervention, therapeutic agent screening, and in diagnostic methods for diseases and/or disorders of erythropoiesis. The panels were discovered using gene expression profiling of erythroid progenitors with Affymetrix HU6800 and HG-U95Av2 chips. Cells from an in vitro growth and differentiation system of SCF-Epo dependent human erythroid progenitors, E-cadherin+/CD36+ progenitors, cord blood, or CD34+ peripheral blood stem cells were analyzed. The HU6800 chip contains probes from 13,000 genes with a potential role in cell growth, proliferation, and differentiation and the HG-U95Av2 chip contains 12,000 full-length, functionally-characterized genes. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L9 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:889462 HCAPLUS

DOCUMENT NUMBER:

137:380918

TITLE:

Survivin-interacting proteins and

uses in drug screening

INVENTOR(S):

Wettstein, Daniel Albert; Cimbora, Daniel

PATENT ASSIGNEE(S):

Myriad Genetics, Inc., USA

SOURCE:

U.S. Pat. Appl. Publ., 48 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002173026	A1	20021121	US 2002-99924		20020314
PRIORITY APPLN. INFO.:			US 2001-276179P	P	20010315
			IIS 2001-307233P	P	20010723

AB Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of cytoplasmic dynein light chain 1 (HDLC1

),  $\beta\text{-actin}$ , ATP-dependent DNA helicase II 70 kD subunit (DNA helicase II),  $\beta\text{-prime}$  subunit of coatomer complex (COPP), osteopontin alt. transcript 1 (OSTP), Na+/Ca2+-exchange protein 1 (SLC8A1), catenin  $\alpha$  2 (A2-CAT). The protein complexes are useful in screening assays for identifying compds. effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with  $\mathbf{survivin}$  and its  $\mathbf{interacting}$  partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or  $\mathbf{interacting}$  members thereof are also provided.

L9 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:391912 HCAPLUS

DOCUMENT NUMBER:

137:1836

TITLE:

Measurement of DNA methylation for analysis of the

toxicology of substances

INVENTOR (S):

Olek, Alexander; Piepenbrock, Christian; Berlin, Kurt

PATENT ASSIGNEE(S): Epigenomics Ag, Germany SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

## PATENT INFORMATION:

```
PATENT NO.
                         KIND
                                DATE
                                            APPLICATION NO.
                                                                    DATE
     -----
                                            ------
                                                                    _____
                         ----
                                -----
                                            WO 2001-EP12951
                                                                    20011108
     WO 2002040710
                          A2
                                20020523
     WO 2002040710
                                20030530
                          A3
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
                                            DE 2000-10056802
     DE 10056802
                                20020529
                          A1
                                            AU 2002-23672
    AU 2002023672
                          Α5
                                20020527
                                                                    20011108
     EP 1337668
                         A2
                                20030827
                                            EP 2001-996625
                                                                    20011108
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                         T2
                                            JP 2002-543021
     JP 2004513650
                                20040513
                                                                    20011108
     US 2004048279
                                            US 2003-416905
                          Α1
                                20040311
                                                                    20030514
PRIORITY APPLN. INFO.:
                                            DE 2000-10056802 A 20001114
                                                               W 20011108
                                            WO 2001-EP12951
```

The invention relates to a method for anal. of the toxicol. of a substance AB by measuring its effects using changes in DNA methylation as an indicator of toxicol. According to the invention, a DNA sample is taken from an organism or a cell culture which has been exposed to a specific substance which is to be examined on account of its toxicol. effect. The DNA contained in said sample is chemical pre-treated and the base sequence of a section of the modified DNA is determined The preferred method is to convert cytosine in CpG dinucleotides to uracil using bisulfite. Probes specific for cytosine- or uracil-containing DNA can be used to detect changes in methylation. From there, a characteristic methylation state or a characteristic methylation model is determined for the sample. By comparison with data from methylation states of other samples, the effect of a substance on the organism or the cell culture is determined and/or compared to other substances in toxicol. terms. A panel of sequences that can be used to analyze the effects of poisons is described.

```
L9 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
```

ACCESSION NUMBER:

2002:72748 HCAPLUS

DOCUMENT NUMBER:

INVENTOR(S):

136:146104

TITLE:

Human stress genes identified using DNA microarrays

Chenchik, Alex; Lukashev, Matvey E.

PATENT ASSIGNEE(S):

Clontech, USA

SOURCE:

U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S.

Ser. No. 441,920.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002009730	A1	20020124	US 2001-782909		20010213
PRIORITY APPLN. INFO.:			US 1998-222256	B2	19981228
			US 1999-440305	R2	19991117

A2 19991117 US 1999-441920 Human stress arrays and methods for their use are provided. The subject AΒ arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The average length of the polynucleotide probes is between 50 to 1000 nucleotides. The d. of the spots on the array did not exceed 400/cm2 and the spots had a diameter ranging between 10 to 5000  $\mu\text{m}\text{.}$  Furthermore, the number of polynucleotide probe spots on the array ranged between 50 to 2000 nucleotides. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes. 236 Different human stress genes were identified using this approach.

L9 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2001:338762 HCAPLUS

DOCUMENT NUMBER:

134:362292

TITLE:

Methods of determining individual hypersensitivity to

a pharmaceutical agent from gene expression profile

INVENTOR(S):

Farr, Spencer

PATENT ASSIGNEE(S):

Phase-1 Molecular Toxicology, USA

SOURCE:

PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PAT	ENT :	NO.			KIN	D	DATE			APPL	ICAT	ION 1	NO.		D	ATE	
						_									-		
WO	2001	0329	28		A2		2001	0510	1	WO 2	000-	US30	474		2	0001	103
WO	2001	0329	28		<b>A</b> 3		2002	0725									
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	ΒA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,
		HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	·KZ,	LC,	LK,	LR,	LS,	LT,
		LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	PL,	PT,	RO,	RU,
•		SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	ΤZ,	UA,	UG,	US,	UΖ,	VN,
		YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM				
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZW,	AT,	BE,	CH,	CY,
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG		
PRIORITY	APP	LN.	INFO	. :					1	US 1	999-	1653	98P	]	P 1:	9991	105
									1	US 2	000-	1965	71P	]	P 2	00004	411

The invention discloses methods, gene databases, gene arrays, protein AΒ arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd, to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and

apparatus useful for identifying hypersensitivity in a subject are also disclosed.

## => d his ful

```
FILE 'HCAPLUS' ENTERED AT 14:58:02 ON 04 NOV 2004
                 E WETTSTEIN DANIEL ALBERT/AU
                 E CIMBORA DANIEL/AU
                 E WETTSTEIN DANIEL ALBERT/AU
 L1
              17 SEA ABB=ON ("WETTSTEIN DANIEL"/AU OR "WETTSTEIN DANIEL A"/AU
                 OR "WETTSTEIN DANIEL ALBERT"/AU)
                 E CIMBORA DANIEL/AU
 L2
              24 SEA ABB=ON ("CIMBORA DAN"/AU OR "CIMBORA DANIEL"/AU OR
                 "CIMBORA DANIEL M"/AU OR "CIMBORA DANIEL MICHAEL"/AU)
               1 SEA ABB=ON L1 AND L2
 L3
 L4
                 ANALYZE L3 1-1 CT :
                                           17 TERMS
      FILE 'REGISTRY' ENTERED AT 15:14:29 ON 04 NOV 2004
               1 SEA ABB=ON SURVIVIN/CN
 L5
               0 SEA ABB=ON HDLC1/CN
 L6
                 E HDLC1/CN
                 E HDLC 1/CN
                 E CYTOPLASMIC DYNEIN/CN
                 E CYTOPLASMIC DYNEIN/CN
L7
               1 SEA ABB=ON "CYTOPLASMIC DYNEIN LIGHT CHAIN 1 (HUMAN CELL LINE
                 HUT-78 T CELL LIBRARY GENE HDLC1) "/CN
      FILE 'HCAPLUS' ENTERED AT 15:17:21 ON 04 NOV 2004
               5 SEA ABB=ON (L5 OR ?SURVIVIN?) AND (L7 OR ?HDLC1? OR ?CYTOPLASM
L8
                 IC? (W) ?DYNEIN? (W) ?LIGHT? (W) ?CHAIN? (W) 1)
               5 SEA ABB=ON L8 AND (?FUSE? OR ?FUSION? OR ?COVALEN? OR
L9
                                  5 cità from CA Plus
                 ?INTERACT?)
LII DEA ABB=ON L9 Ohits from other d.b. 5

If you would like a more generic search,

please let me know.
      FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 15:19:04 ON
```

Harris 10/099,924

04/11/2004

=> d ibib abs ind 13 1-1

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:889462 HCAPLUS

DOCUMENT NUMBER:

137:380918

TITLE:

Survivin-interacting proteins and uses in drug

screening

INVENTOR(S):

. · · · · · · ·

Wettstein, Daniel Albert; Cimbora,

Daniel

PATENT ASSIGNEE(S):

Myriad Genetics, Inc., USA
U.S. Pat. Appl. Publ., 48 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

SOURCE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
		<b></b>				
US 2002173026	A1	20021121	US 2002-99924	20020314		
PRIORITY APPLN. INFO.:			US 2001-276179P P	20010315		
			US 2001-307233P P	20010723		

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of cytoplasmic dynein light chain 1 (HDLC1),  $\beta$ -actin, ATP-dependent DNA helicase II 70 kD subunit (DNA helicase II),  $\beta$ -prime subunit of coatomer complex (COPP), osteopontin alt. transcript 1 (OSTP), Na+/Ca2+-exchange protein 1 (SLC8A1), catenin  $\alpha$  2 (A2-CAT). The protein complexes are useful in screening assays for identifying compds. effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

IC ICM C12N009-22

ICS C12N009-64; C12P021-02; C12N005-06

NCL 435199000; 435226000; 435069100; 435320100; 435325000

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 7

ST protein complexe survivin interacting drug screening

IT Protein motifs

(DNA binding domain; survivin-interacting proteins and uses in drug screening)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(DNA helicase II, as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)

IT Drug screening

(affecting interaction of survivin with interacting partners; survivin-interacting proteins and uses in drug screening)

IT Osteopontin

RL: BSU (Biological study, unclassified); BIOL (Biological study) (alt. transcript 1 (OSTP), as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)

IT Transport proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (calcium-sodium exchanger, 1 (SLC8A1), as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(complexes, of survivin with interacting partners; survivin-interacting proteins and uses in drug screening) ITYeast (determination interaction of survivin with interacting partners in; survivin-interacting proteins and uses in drug screening) ITAntibodies and Immunoglobulins RL: BSU (Biological study, unclassified); BIOL (Biological study) (for survivin-interacting protein complex; survivin-interacting proteins and uses in drug screening) IT Dyneins RL: BSU (Biological study, unclassified); BIOL (Biological study) (light chain (HDLC1), as survivin-interacting partner; survivin-interacting proteins and uses in drug screening) Fusion proteins (chimeric proteins) IT RL: BSU (Biological study, unclassified); BIOL (Biological study) (of survivin fused with interacting partners; survivin-interacting proteins and uses in drug screening) ITMolecular association (of survivin with interacting partners; survivin-interacting proteins and uses in drug screening) ITDrug design Molecular cloning Protein microarray technology (survivin-interacting proteins and uses in drug screening) IT Protein motifs (transcription-activation domain; survivin-interacting proteins and uses in drug screening) Genetic methods IT (two-hybrid screening; survivin-interacting proteins and uses in drug screening) TT Catenins RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\alpha 2$ , as survivin-interacting partner; survivin-interacting proteins and uses in drug screening) TT Actins RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\beta$ -, as survivin-interacting partner; survivin-interacting proteins and uses in drug screening) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\beta$ -prime subunit of coatomer complex (COPP), as survivin-interacting partner; survivin-interacting proteins and uses in drug screening) 371761-91-0, Survivin TΤ RL: BSU (Biological study, unclassified); BIOL (Biological study) (survivin-interacting proteins and uses in drug screening) 141144-83-4, GenBank K00790 141682-88-4, GenBank M94151 141878-02-6, TT

IT 141144-83-4, GenBank K00790 141682-88-4, GenBank M94151 141878-02-6,
 GenBank M91368 147387-73-3, GenBank S38729 335577-39-4, GenBank
 BC007016 391541-65-4, GenBank X70476 391781-88-7, GenBank U32944
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(survivin-interacting proteins and uses in drug screening)

=> 0 L4		ANA	ALYZE L	3 1-1 C	r : 17 TERMS
TERN	4 # 	# occ	# DOC	% DOC	СТ
	1	, 2	1	100.00	PROTEIN MOTIFS
	2	. 2	1	100.00	PROTEINS
	3	1	1	100.00	ACTINS
	4	1	1	100.00	ANTIBODIES AND IMMUNOGLOBULINS
	5	1	1	100.00	CATENINS
	6	1	1	100.00	DRUG DESIGN
	7	1	1	100.00	DRUG SCREENING
	8	1	1	100.00	DYNEINS
	9	1		100.00	ENZYMES, BIOLOGICAL STUDIES
	10	1	1	100.00	FUSION PROTEINS (CHIMERIC PROTEINS)
	11	1	1	100.00	GENETIC METHODS
	12	1	1	100.00	MOLECULAR ASSOCIATION
	13	1	1	100.00	MOLECULAR CLONING
	14	1	1	100.00	OSTEOPONTIN
	15	1	1	100.00	PROTEIN MICROARRAY TECHNOLOGY
	16	1	1	100.00	TRANSPORT PROTEINS
	17	1	1	100.00	YEAST

\*\*\*\*\*\* END OF L4 \*\*\*